Crescita Therapeutics (CTX) News Today Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Chordia Therapeutics Advances Cancer Drug DevelopmentNovember 20 at 2:21 AM | markets.businessinsider.comPromising Phase 1 Results of Compass Therapeutics’ CTX-471 Highlight Potential for Advanced Solid Tumors TreatmentNovember 11, 2024 | markets.businessinsider.comCompass Therapeutics presents biomarker data related to CTX-471November 8, 2024 | markets.businessinsider.comCrescita Therapeutics Announces Approval of Normal Course Issuer BidSeptember 24, 2024 | businesswire.comCrescita Therapeutics Inc. Reports Second Quarter 2024 ResultsAugust 7, 2024 | finanznachrichten.deCrescita Reports Second Quarter 2024 ResultsAugust 7, 2024 | financialpost.comBuy Rating Affirmed on Compass Therapeutics as Clinical Trials of CTX-009 Show Promise in Biliary Tract Cancer TreatmentAugust 6, 2024 | markets.businessinsider.comClosing Bell: Crescita Therapeutics Inc up on Monday (CTX)July 31, 2024 | theglobeandmail.comCrescita secures four-year term contract manufacturing revenue from largest CMO clientJuly 22, 2024 | msn.comCrescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 YearsJuly 22, 2024 | finance.yahoo.comLeading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year AgreementJuly 19, 2024 | finance.yahoo.comCrescita Reports First Quarter 2024 ResultsMay 8, 2024 | finance.yahoo.comCTNM Contineum Therapeutics, Inc.April 18, 2024 | seekingalpha.comCrescita Reports Q4 and Fiscal 2023 ResultsMarch 13, 2024 | finance.yahoo.comCrescita Therapeutics Inc CTXFebruary 17, 2024 | morningstar.comClosing Bell: Crescita Therapeutics Inc up on Wednesday (CTX)December 14, 2023 | theglobeandmail.comCrescita Reports Third Quarter 2023 ResultsNovember 8, 2023 | finance.yahoo.comClosing Bell: Crescita Therapeutics Inc up on Thursday (CTX)November 4, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Friday (CTX)September 30, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Tuesday (CTX)September 1, 2023 | theglobeandmail.comCrescita Reports Second Quarter 2023 ResultsAugust 9, 2023 | finance.yahoo.comClosing Bell: Crescita Therapeutics Inc flat on Monday (CTX)August 6, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Friday (CTX)July 29, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Monday (CTX)July 18, 2023 | theglobeandmail.comSubdued Growth No Barrier To Crescita Therapeutics Inc.'s (TSE:CTX) PriceJune 8, 2023 | finance.yahoo.comCroma-Pharma: Launch of topical anaesthetic Pliaglis® in EuropeJune 1, 2023 | finance.yahoo.comCrescita Reports First Quarter 2023 ResultsMay 11, 2023 | finance.yahoo.comClosing Bell: Crescita Therapeutics Inc flat on Friday (CTX)April 15, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc up on Tuesday (CTX)April 12, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Thursday (CTX)April 11, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc flat on Wednesday (CTX)April 8, 2023 | theglobeandmail.comClosing Bell: Crescita Therapeutics Inc down on Wednesday (CTX)April 6, 2023 | theglobeandmail.comCrescita Therapeutics GAAP EPS of C$0.06, revenue of C$6MMarch 18, 2023 | seekingalpha.comCrescita Therapeutics Inc. Reports Q4 and Fiscal 2022 ResultsMarch 15, 2023 | finanznachrichten.deCrescita Therapeutics GAAP EPS of $0.06, revenue of $6MMarch 15, 2023 | msn.comCrescita Therapeutics Q4 Profit Rises, But Revenues DeclineMarch 15, 2023 | markets.businessinsider.comCrescita Reports Q4 and Fiscal 2022 ResultsMarch 15, 2023 | finance.yahoo.comCTX:CA Crescita Therapeutics Inc.November 16, 2022 | seekingalpha.comCrescita Therapeutics Third Quarter 2022 Earnings: EPS: CA$0.009 (vs CA$0.043 loss in 3Q 2021)November 11, 2022 | finance.yahoo.comCrescita Reports Third Quarter 2022 ResultsNovember 9, 2022 | finance.yahoo.comCrescita Therapeutics GAAP EPS of C$0.00, revenue of C$6.51MAugust 12, 2022 | seekingalpha.comCrescita Therapeutics IncAugust 10, 2022 | reuters.comCrescita Reports Second Quarter 2022 ResultsAugust 10, 2022 | finance.yahoo.comCrescita Therapeutics Inc. (CTX.TO)August 6, 2022 | ca.finance.yahoo.comCrescita Reports First Quarter 2022 ResultsMay 11, 2022 | finance.yahoo.comCrescita to Present at Bloom Burton & Co. Healthcare Investor ConferenceApril 21, 2022 | financialpost.comCrescita Reports Q4 and Fiscal 2021 ResultsMarch 23, 2022 | finance.yahoo.comStocks in play: Crescita Therapeutics Inc.December 19, 2021 | ca.finance.yahoo.comCrescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®December 13, 2021 | finance.yahoo.comCrescita Therapeutics Inc (CTX)December 2, 2021 | investing.com Get Crescita Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] CTX Media Mentions By Week CTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTX News Sentiment▼-1.320.46▲Average Medical News Sentiment CTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTX Articles This Week▼10▲CTX Articles Average Week Get Crescita Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LABS News CWEB News DB News WLLW News MPH News NDVA News VPH News ENTG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:CTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescita Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
